LOS ANGELES, CA — VERAXA Biotech (NASDAQ: VRXA) said shareholders approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented.

The approved measures include the introduction of conditional share capital for shareholder options and warrants, the implementation of a capital band through December 31, 2030, and an increase in the maximum size of the board of directors from five to seven members.

VERAXA said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities, and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.

The approval of conditional share capital allows the company to issue shares for options and warrants, which can be used to attract and retain talent, raise capital, or facilitate partnerships. The capital band gives the board authority to increase or decrease share capital within a specified range without further shareholder approval, providing additional operational flexibility. Expanding the board from five to seven members allows for the addition of directors with diverse expertise, which may strengthen oversight and strategic guidance.

For a company developing antibody-based oncology programs, these governance tools can matter because they affect how quickly VERAXA can adapt its financing and board structure as it advances its pipeline. The changes come as VERAXA continues to develop bispecific T cell engagers and bispecific ADCs using technologies originating from the European Molecular Biology Laboratory (EMBL), with its proprietary BiTAC platform remaining central to that work.

“Today’s vote demonstrates strong shareholder confidence in our strategy and governance,” said a company spokesperson. “The new framework positions us to capitalize on opportunities and drive long-term growth.”

The full press release is available at For the latest news and updates on VRXA, visit the company’s newsroom at

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially. Investors should review the risk factors detailed in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.